Ligand Pharmaceuticals Incorporated (LGND)

$118.60 $2.40 (2.06%) 4:37 PM 12/10/24
NASDAQ | $USD | Biotechnology

Stock Data

  • Market Cap

    $2.36B
  • Day's Range

    $114.00 - $119.16
  • Volume

    110,330
  • 52 Week Low / High

    $60.28 - $129.90
  • PE Ratio

    50.33x
  • PEG Ratio

    1.53
  • Dividend Frequency

    -

LGND's Dividend
$0.46
Amount
-
Dividend Yield
Jul 2
Payment Date
-
Annual Dividend Amount
Dividend Streak
Hypothetical 10k Investment Jan 1, 2020
Capital Growth
Dividend Return to Date
Dividend Payout year Est.
Expenses
Total Return
Total Return %
Analyists Ranking
3
Strong Buy
4
Buy
0
Hold
0
Sell
0
Strong Sell
$112.67
Target Price

Company News

  • LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024

    By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...

  • LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024

    By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...

  • Can Mixed Fundamentals Have A Negative Impact on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Current Share Price Momentum? — Sep 25th, 2024

    Ligand Pharmaceuticals (NASDAQ:LGND) has had a great run on the share market with its stock up by a significant 28% over the last three months. But the company's key financial indicators appear to be differing across the board and that makes us question whether or not the company's current...

  • Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

    Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

  • LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024

    By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...

  • Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

    Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

  • LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024

    By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...

  • Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

    Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

  • Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

    Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

  • Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

    Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

  • Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

    Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

  • LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024

    By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...

  • LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024

    By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...

  • Can Mixed Fundamentals Have A Negative Impact on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Current Share Price Momentum? — Sep 25th, 2024

    Ligand Pharmaceuticals (NASDAQ:LGND) has had a great run on the share market with its stock up by a significant 28% over the last three months. But the company's key financial indicators appear to be differing across the board and that makes us question whether or not the company's current...

  • LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024

    By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...

  • Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

    Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

  • Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

    Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

  • LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024

    By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...

  • Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

    Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

Similar Stocks

No similar stocks found.

Want to be notified on dividend changes?

Start manging your portfolio today.

Sign up for free